ETFChannel.com
SRPT Description — Sarepta Therapeutics Inc

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.

Company Name: 
Sarepta Therapeutics Inc
Website: 
www.sarepta.com
Sector: 
Biotechnology
Number of ETFs Holding SRPT: 
44
Total Market Value Held by ETFs: 
$1,241,089,259.96
Total Market Capitalization: 
$11,269,000,000
% of Market Cap. Held by ETFs: 
11.01%
 ETF   SRPT Weight   SRPT Amount 
 VTI   0.03%   $312,119,749         
 VB   0.22%   $264,225,147         
 VBK   0.53%   $152,588,185         
 VXF   0.17%   $146,148,492         
 XBI   0.93%   $73,106,772         
 FBT   3.17%   $49,170,661         
 IWP   0.30%   $35,799,887         
 IWF   0.06%   $34,089,252         
 VHT   0.17%   $33,553,348         
 FXH   1.96%   $32,095,047         
List of all 44 ETFs holding SRPT »
Quotes delayed 20 minutes

Email EnvelopeFree SRPT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.47 out of 4)
53rd percentile
(ranked higher than approx. 53% of all stocks covered)

Analysts Forecast:
SRPT Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding SRPT | Sarepta Therapeutics Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.